Last reviewed · How we verify

COLM Study Research Organization — Portfolio Competitive Intelligence Brief

COLM Study Research Organization pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
olmesartan medoxomil / amlodipine or azelnidipine olmesartan medoxomil / amlodipine or azelnidipine marketed Angiotensin II receptor blocker / Calcium channel blocker combination Angiotensin II type 1 receptor (AT1R); L-type voltage-gated calcium channels Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Boryung Pharmaceutical Co., Ltd · 1 shared drug class
  2. Chong Kun Dang Pharmaceutical · 1 shared drug class
  3. Daiichi Sankyo Co., Ltd. · 1 shared drug class
  4. HK inno.N Corporation · 1 shared drug class
  5. Handok Inc. · 1 shared drug class
  6. Institut für Pharmakologie und Präventive Medizin · 1 shared drug class
  7. Novartis · 1 shared drug class
  8. University of Pavia · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for COLM Study Research Organization:

Cite this brief

Drug Landscape (2026). COLM Study Research Organization — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/colm-study-research-organization. Accessed 2026-05-15.

Related